TC
PGNX

TFS Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

TFS Capital’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-78,134
Closed -$531K – 500
2017
Q2 		$531K Buy
+78,134
New +$577K 0.21% 163
2017
Q1 		– Sell
-174,408
Closed -$1.51M – 939
2016
Q4 		$1.51M Buy
+174,408
New +$1.29M 0.4% 42
2016
Q3 		– Sell
-60,575
Closed -$256K – 1097
2016
Q2 		$256K Sell
60,575
-75,228
-55% -$363K 0.05% 658
2016
Q1 		$592K Sell
135,803
-262,480
-66% -$1.17M 0.09% 399
2015
Q4 		$2.44M Buy
398,283
+334,774
+527% +$2.19M 0.26% 123
2015
Q3 		$363K Sell
63,509
-239,232
-79% -$1.84M 0.04% 623
2015
Q2 		$2.26M Sell
302,741
-387,018
-56% -$2.34M 0.22% 126
2015
Q1 		$4.13M Buy
689,759
+226,019
+49% +$1.42M 0.4% 43
2014
Q4 		$3.51M Buy
463,740
+438,538
+1,740% +$2.62M 0.33% 61
2014
Q3 		$131K Sell
25,202
-63,781
-72% -$318K 0.01% 943
2014
Q2 		$384K Sell
88,983
-60,202
-40% -$230K 0.03% 742
2014
Q1 		$610K Sell
149,185
-5,549
-4% -$28.4K 0.04% 655
2013
Q4 		$825K Sell
154,734
-39,167
-20% -$172K 0.04% 637
2013
Q3 		$973K Buy
193,901
+85,836
+79% +$466K 0.04% 591
2013
Q2 		$482K Buy
+108,065
New +$485K 0.02% 914

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

TFS Capital's PGNX Position: Q3 2017 in Review

TFS Capital sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 78,134 shares — an estimated $531K sold.

TFS Capital first reported a position in PGNX in Q2 2013 and held it in 15 quarters. The position peaked at $4.13M in Q1 2015. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

  • TFS Capital reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 78,134 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $531K.
  • TFS Capital first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • TFS Capital's Progenics Pharmaceuticals Inc position peaked at $4.13M in Q1 2015.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.